|
|
Article: GSK Spin-Off Affymax Generates $20M In Private Financing Round.
- Article from:
- BIOWORLD Today
- Article date:
- November 4, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Staff Writer
Affymax Inc. closed a $20 million private round of financing that coincided with the drug discovery and development firm's appointment of a new chief executive.
"Its pipeline of clinical candidates have been identified and continue to move forward," Lori Rafield, a board member at Affymax and a general partner at lead investor Apax Partners & Co., told BioWorld Today. "Combining that with [new President and CEO] Arlene Morris joining, and to us it was an outstanding investment opportunity."
The Palo Alto, Calif.-based company said the funding would last more than two years, providing enough cushion to support plans to push its ...
Related newspaper, magazine, and journal articles:
|
|
Article: Affymax Series D Garners $60M To Boost Hematide By Randall ...
BIOWORLD Today;
July 19, 2005 ;
700+ words
... ... data," Morris told BioWorld Today, but getting a deal earlier would let Affymax "more aggressively ... based EntreMed Inc., Affymax has a tissue factor ... of research. (See BioWorld Today, Oct. 27, 2004 ... also of New York. Affymax said Hironori Hozoji ...
|
|